Successful proof of concept studies
Brisbane, Feb 7, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) is pleased to report positive efficacy data from its in vitro Proof of Concept (PoC) studies of its Gastrointestinal ReProgramming (GaRP) product. GaRP is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome.
The GaRP dietary supplement unlike those commonly marketed, selectively targets specific formulation components to the small intestine and colon where they can exert their greatest therapeutic effect.
Gastrointestinal disorders and diseases such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD: Crohn's disease and Ulcerative Colitis) are characterised by an increase in pro-inflammatory bacteria, increased intestinal permeability and inflammation.
IBS affects around 11% of the global population1 and 50% of patients2 turn to dietary supplements and complementary medicines to manage the symptoms of their disease. IBD affects >5 million patients worldwide3 and due to the failure of current drugs, 30-50% of patients4 turn to complementary and alternative medicines. Anatara consulted with gastroenterologists to confirm the potential role of GaRP in filling the unmet needs of IBS and IBD patients.
Anatara used industry-standard in vitro gut models to evaluate the performance of the proprietary GaRP formulation which demonstrated that Anatara's GaRP dietary supplement was efficacious and:
- Reduced production of pro-inflammatory proteins by gut and inflammatory cells by >85%;
- Reduced the attachment and invasion of IBD and IBS pro-inflammatory bacteria into healthy gut cells by >95%;
- Protected and maintained gut integrity.
Following these positive results, Anatara will commence planning for a human clinical study for IBS with patient recruitment anticipated to start in the second half of 2019. The human study will be observational with the potential to support health claims and is anticipated to be funded from existing resources.
In parallel, Anatara will move GaRP into the final stage of pre-clinical development for IBD with mouse pre-clinical studies expected to be completed by end of July 2019.
Anatara's CEO, Mr Steven Lydeamore said, "The results we've seen from these data and the feedback from gastroenterologists to date have been very positive and indicate that GaRP may be a breakthrough dietary product. This is a major milestone for Anatara's GaRP development program bringing us closer to partnering."
What is the aim of Anatara's Gastrointestinal ReProgramming (GaRP) dietary supplement?
GaRP is a natural daily supplement that provides a unique and patented combination of clinically studied ingredients to deliver a wholistic approach to gut health.
GaRP was specifically developed to improve and maintain gastrointestinal health and assist IBD and IBS patients manage their disease and the associated symptoms. It achieves this by:
- Restoring balance to the gut microbiome, which can improve digestive function and boost the immune system;
- Reducing gastrointestinal inflammation, delivering natural digestive support and providing on-going gastrointestinal aid to help reduce digestive discomfort, better digest food and improve nutrient absorption;
- Promoting and supporting mucosal healing which in turn protects the lining in the gut;
- Restoring intestinal epithelial barrier integrity.
Due to the potential mechanism of action and safety it is envisaged that the GaRP product could be used as a sole therapy and as an adjunct therapy in combination with current IBD and IBS prescription medications.
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
